Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2019 | Radium-223 label change

Bertrand Tombal, MD, PhD, of the Cliniques Universitaires Saint-Luc, Brussels, Belgium give his opinion on the European Medicines Agency’s (EMA) change to the label for Radium-223 for the treatment of metastatic castration-resistant prostate cancer. This interview was recorded at the American Society of Oncology (ASCO) 2019 Annual Meeting, held in Chicago, IL.